NCI Translational Research Enterprise Will Be Analyzed By New Task Force
This article was originally published in The Pink Sheet Daily
Executive Summary
National Cancer Institute Director von Eschenbach says the task force will examine the landscape of NCI-supported translational research, which includes cancer centers and SPORE programs. The group will identify opportunities to enhance the discovery, development and delivery of cancer therapeutics.
You may also be interested in...
“Pharmaco-Metabonomics” Holds Promise for Personalized Drug Therapies, Researchers Say
The method uses a combination of advanced chemical analysis and mathematical modeling to predict drug response.
NCI-Funded Researchers Are Patenting At Surprisingly High Rate, Report Says
More than one in four National Cancer Institute-funded scientists start their own healthcare companies based on their own discoveries.
U.S. Overtakes Europe In New Drug Introductions, Study Finds
U.S. overtakes Europe in innovation between 1993 and 2003, introducing the most first-in-class, biotech and orphan products in the global market, according to a study authored by a Duke University economics professor